Your browser is no longer supported. Please, upgrade your browser.
KURA Kura Oncology, Inc. daily Stock Chart
KURA [NASD]
Kura Oncology, Inc.
Index- P/E- EPS (ttm)-1.56 Insider Own0.10% Shs Outstand45.41M Perf Week8.37%
Market Cap996.07M Forward P/E- EPS next Y-1.98 Insider Trans0.00% Shs Float40.46M Perf Month5.06%
Income-68.40M PEG- EPS next Q-0.42 Inst Own73.80% Short Float7.00% Perf Quarter84.23%
Sales- P/S- EPS this Y12.40% Inst Trans2.80% Short Ratio3.77 Perf Half Y31.98%
Book/sh4.47 P/B4.00 EPS next Y-9.40% ROA-27.70% Target Price24.38 Perf Year-12.70%
Cash/sh3.89 P/C4.59 EPS next 5Y19.93% ROE-30.30% 52W Range6.35 - 21.42 Perf YTD29.96%
Dividend- P/FCF- EPS past 5Y-42.90% ROI- 52W High-16.57% Beta2.29
Dividend %- Quick Ratio15.20 Sales past 5Y- Gross Margin- 52W Low181.42% ATR0.93
Employees62 Current Ratio15.20 Sales Q/Q- Oper. Margin- RSI (14)55.82 Volatility4.18% 5.81%
OptionableYes Debt/Eq0.04 EPS Q/Q-15.80% Profit Margin- Rel Volume0.26 Prev Close17.88
ShortableYes LT Debt/Eq0.03 EarningsMay 04 AMC Payout- Avg Volume752.70K Price17.87
Recom1.70 SMA202.93% SMA508.56% SMA20030.07% Volume194,326 Change-0.06%
Jul-07-20Initiated Credit Suisse Outperform $27
May-05-20Initiated Barclays Overweight $24
Jul-18-19Initiated Deutsche Bank Buy $28
Nov-09-18Initiated Piper Jaffray Overweight
Aug-01-18Initiated H.C. Wainwright Buy $31
Oct-13-16Resumed Leerink Partners Outperform $15
Jan-22-16Initiated JMP Securities Mkt Outperform
Dec-30-15Initiated Oppenheimer Outperform $16
Dec-16-15Initiated Citigroup Buy
Jun-16-20 10:46AM  
Jun-11-20 07:30AM  
May-29-20 08:00AM  
May-13-20 05:00PM  
03:18AM  
May-08-20 04:03PM  
May-07-20 07:30AM  
May-06-20 09:00AM  
May-05-20 04:01PM  
11:30AM  
May-04-20 04:05PM  
Apr-29-20 07:30AM  
Apr-28-20 03:09PM  
Mar-10-20 03:18AM  
Mar-03-20 07:30AM  
Feb-25-20 04:03PM  
Feb-19-20 04:05PM  
Feb-18-20 04:05PM  
Jan-24-20 10:44AM  
Jan-23-20 04:05PM  
Jan-21-20 04:09AM  
Jan-09-20 07:30AM  
Jan-06-20 07:30AM  
Dec-16-19 07:30AM  
Dec-10-19 02:21PM  
Dec-08-19 12:00PM  
Nov-26-19 07:30AM  
Nov-25-19 05:51AM  
Nov-15-19 04:29PM  
Nov-12-19 07:30AM  
Nov-09-19 02:26PM  
Nov-06-19 09:06AM  
Nov-05-19 04:05PM  
Nov-04-19 07:30AM  
Oct-30-19 07:30AM  
Oct-29-19 11:50AM  
Oct-23-19 04:05PM  
Oct-16-19 04:30PM  
Oct-15-19 07:30AM  
Oct-01-19 01:05AM  
Sep-16-19 07:30AM  
Sep-03-19 07:30AM  
Aug-29-19 07:30AM  
Aug-12-19 04:05PM  
Aug-07-19 07:30AM  
Aug-03-19 12:08AM  
Jul-25-19 07:30AM  
Jul-24-19 07:30AM  
Jul-11-19 07:30AM  
Jul-02-19 09:15AM  
Jun-23-19 08:50AM  
08:48AM  
Jun-21-19 04:30PM  
Jun-18-19 11:31PM  
04:01PM  
10:46AM  
Jun-17-19 09:31AM  
Jun-14-19 10:03AM  
07:48AM  
07:00AM  
May-15-19 12:14PM  
May-09-19 01:15PM  
May-07-19 08:49PM  
05:54PM  
04:05PM  
Apr-30-19 07:30AM  
Apr-25-19 12:36PM  
Apr-02-19 04:04PM  
Mar-29-19 07:10AM  
Mar-27-19 07:16AM  
Mar-06-19 07:30AM  
Mar-05-19 07:13PM  
04:03PM  
07:30AM  
Feb-26-19 07:30AM  
Feb-20-19 07:30AM  
Feb-19-19 07:40AM  
Jan-18-19 10:00AM  
Jan-03-19 07:30AM  
Dec-15-18 11:21PM  
Dec-03-18 09:19AM  
Dec-02-18 12:00PM  
Nov-30-18 07:50AM  
Nov-28-18 07:30AM  
Nov-08-18 07:30AM  
Nov-06-18 07:30AM  
Nov-05-18 06:14PM  
04:05PM  
07:30AM  
Nov-01-18 09:00AM  
Oct-29-18 07:30AM  
Oct-25-18 08:53AM  
Oct-23-18 09:15AM  
Oct-22-18 02:20PM  
08:45AM  
Sep-26-18 04:05PM  
Aug-30-18 07:30AM  
Aug-20-18 11:45AM  
Aug-07-18 04:05PM  
Aug-06-18 04:36PM  
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.